• LAST PRICE
    19.8100
  • TODAY'S CHANGE (%)
    Trending Up0.3100 (1.5897%)
  • Bid / Lots
    19.8000/ 5
  • Ask / Lots
    19.8200/ 6
  • Open / Previous Close
    19.5000 / 19.5000
  • Day Range
    Low 19.4500
    High 19.9800
  • 52 Week Range
    Low 3.0600
    High 20.3700
  • Volume
    271,623
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 19.5
TimeVolumeADMA
09:32 ET1891319.545
09:34 ET329719.51
09:36 ET488519.63
09:38 ET257119.68
09:39 ET1119919.6453
09:41 ET220119.65
09:43 ET377819.67
09:45 ET477519.62
09:48 ET414819.65
09:50 ET342719.59
09:52 ET150019.65
09:54 ET542819.66
09:56 ET454619.698
09:57 ET846219.7
09:59 ET5291119.84
10:01 ET894319.91
10:03 ET2666019.88
10:06 ET1522019.92
10:08 ET1202619.92
10:10 ET1661619.9098
10:12 ET1273719.88
10:14 ET60019.81
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADMA
ADMA Biologics Inc
4.5B
140.9x
---
United StatesAXSM
Axsome Therapeutics Inc
4.5B
-14.3x
---
United StatesDNLI
Denali Therapeutics Inc
4.2B
-10.1x
---
United StatesTGTX
TG Therapeutics Inc
3.5B
37.5x
---
United StatesBPMC
Blueprint Medicines Corp
5.7B
-26.2x
---
United StatesCRSP
CRISPR Therapeutics AG
3.9B
-14.2x
---
As of 2024-10-03

Company Information

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Contact Information

Headquarters
465 State Route 17RAMSEY, NJ, United States 07446
Phone
201-478-5552
Fax
201-478-5553

Executives

Independent Chairman of the Board
Steven Elms
President, Chief Executive Officer, Co-Founder, Director
Adam Grossman
Vice Chairman of the Board, Co-Founder
Jerrold Grossman
Chief Financial Officer, Treasurer
Brad Tade
Chief Operating Officer, Senior Vice President - Compliance
Kaitlin Kestenberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.5B
Revenue (TTM)
$330.2M
Shares Outstanding
233.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.62
EPS
$0.14
Book Value
$0.60
P/E Ratio
140.9x
Price/Sales (TTM)
13.8
Price/Cash Flow (TTM)
105.3x
Operating Margin
17.49%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.